Oncotype Dx Breast Recurrence Score® Test
Overview
Oncotype Dx Breast Recurrence Score® Test is a biotechnology company headquartered in Amsterdam, Netherlands, with 5,001-10,000 employees.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Oncotype Dx Breast Recurrence Score® Test in our records. PharmaTek screens the full directory against live FDA enforcement data.
Verified Supplier Partner
Is this Oncotype Dx Breast Recurrence Score® Test? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.